Introduction
Extracellular proteases such as thrombin, trypsin, serin protease 1 and coagulation factors VII and Xa can regulate target cells by cleaving and activating receptors that belong to a family of G-protein-coupled protease-activated receptors (PARs) (Brass and Molino 1997 , Corvera et al. 1997 , Molino et al. 1997 , Camerer et al. 2000 , Vergnolle 2000 . This receptor family has at least four members (PAR1-4). Mechanism of receptor triggering involves proteolytic unmasking of a cryptic N-terminal sequence on the extracellular membrane that acts as a tethered receptor-activating ligand. In general, several proteases can activate a single PAR by cleaving it at specific site and exposing the tethered ligand domain. For example, trypsin, tryptase, coagulation factors VIIa and Xa and certain membrane-anchored proteases can all cleave and activate PAR2, although with varying potencies (Cenac et al. 2003 , Chen et al. 2011 , Rothmeier and Ruf 2012 .
There are short specific synthetic peptides, based on the tethered ligand sequences, designed as PARs 1,2 and 4 agonists (Brass and Molino 1997) . Some authors consider PAR3 as a co-factor for the activation of other PARs and it has no selective activating peptide (Noorbakhsh et al. 2003 , Zhao et al. 2014 . These synthetic peptides have been shown to activate the specific receptors and mimic the effects of the activating proteases for example SLIGKV-NH 2 and 2-Furoyl-LIGRLO-NH 2 are frequently used for PAR2 activation. Due to these selective peptides, the physiological consequences of activating different PARs may be studied and distinguished accurately (Hollenberg et al. 1997 . For the purpose of research there were also developed compounds which are able to act as antagonist, e.g. FSLLRY-NH 2 and GB83 inhibit PAR2.
PARs are present in most body tissues, with the highest expression in the epithelium (lungs, liver, digestive tract, skin, blood vessels) and they are also present in the peripheral and central nervous system (Dery et al. 1998 , Vergnolle et al. 2001b . The physiological effect of their activation varies in different tissues.
PAR2 receptors are known to play important roles in the organism response to tissue injury, notably in the process of inflammation and repair (Dery et al. 1998) . In particular, agonists of PAR2, tryptase and trypsin released from different cell types including mast cells, have widespread proinflammatory effects in part via a neurogenic mechanism (Saifeddine et al. 1996 , Steinhoff et al. 2000 , Seeliger et al. 2003 . PAR2 are expressed on a subset of primary sensory neurons and PAR2 agonists stimulate release of substance P (SP) and calcitonin gene-related peptide (CGRP) in peripheral tissues via activation of peripheral nerve endings (Steinhoff et al. 2000) . It was also reported that PAR2 activation can sensitize adult rat dorsal root ganglion (DRG) neurons in vitro (Steinhoff et al. 2000) . Intraplantar injection of subinflammatory doses of PAR2 agonists in rat and mice induced thermal and mechanical hyperalgesia and elevated Fos protein expression in the spinal cord (Vergnolle et al. 2001a ). All these changes indicate an important role for PAR2 in nociceptive transmission.
This review focuses on the function of PAR2 in the nervous system, particularly in connection with transmission and modulation of nociceptive stimuli at the spinal cord level and with pain.
Mechanisms of PAR2 activation and intracellular signal transduction
PARs are G-protein-coupled receptors (GPCRs), a family of receptors with large seven-transmembrane helical domain protein that sense molecules outside the cell and activate intracellular signaling pathways (Nystedt et al. 1994 , Hoogerwerf et al. 2001 . Thrombin and trypsin are usually regarded as the main activators of PARs. PAR2 is a target for trypsin and other serine proteases, such as mast-cell tryptase, but it is not activated by thrombin (Nystedt et al. 1995 , Nystedt et al. 1996 , Molino et al. 1997 ).
PAR2 lacks a hirudin-like thrombin-binding domain, but trypsin cleavage site was detected in its extracellular N terminus domain (Nystedt et al. 1995) . PAR2 is activated by proteolytic cleavage of its extracellular amino terminus (Hollenberg et al. 1997 , Steinhoff et al. 2000 .
These receptors can be also activated by exogenous proteases, as well as non-proteolytically by exogenous peptide sequences that mimic the final amino acids of the tethered ligand (Hollenberg et al. 1997 ).
The signaling pathways that are triggered by PAR2 activation through the binding to activation molecules on G-proteins (Gq/11, Gi/o) may activate several signaling pathways including phospholipases, Jun N-terminal kinase and p44/42 mitogen-activated protein kinase (MAPK), ERK1/2, phosphatidylinositol 3-kinase (PI3K), adenylate cyclase (AC), protein kinase C (PKC), protein kinase A (PKA) and members of the SRC-family of tyrosine kinases , Suen et al. 2010 , Chen et al. 2011 , Bao et al. 2015 .
These signaling pathways can affect various cellular activities -proliferation, gene transcription, morphological changes, motility and survival , Kawabata et al. 2004 . PAR2 activation was also reported to result in up/down-regulation of about 2500 genes that are important mainly for cell metabolism (around 1000), cell cycle, complement and MAPK pathway, sirtuin enzymes, histone deacetylases and inflammatory cytokines (Suen et al. 2010) .
Expression of PAR2 in the nervous system
High density expression of PAR2 receptors was documented in neurons of hippocampus, cortex, amygdala, thalamus, hypothalamus, striatum and in DRG neurons in rats (Striggow et al. 2001) . All four PARs are also present in astrocytes culture from rat brain (Wang et al. 2002) . PAR2 are expressed on neurons and astrocytes also in human CNS (D'Andrea et al. 1998 , Noorbakhsh et al. 2006 . Localization on guinea-pig myenteric and submucosal neurons was demonstrated earlier (Corvera et al. 1999) . For the presence of PAR2 in the spinal cord dorsal horn exist mainly functional electrophysiological evidence (Alier et al. 2008 , Fujita et al. 2009 , Huang et al. 2011 , while recently PAR2 were detected also using western blot analysis in the rat spinal cord tissue (Chen et al. 2015) . PAR2 were immunohistochemically detected in many small-sized and some medium-to large-sized DRG neurons (Steinhoff et al. 2000 , Dai et al. 2004 ). Significant population of small DRG neurons expressing TRPV1 receptors, also showed expression of PAR2 (Amadesi et al. 2004 , Dai et al. 2004 , suggesting possible interactions between them.
Activation of PAR2 in neuronal tissue
Trypsin and tryptase are known as the main PAR2-activating proteases. Potentially, the main source of tryptase to activate neural PAR2 are mast cells that have been found in the choroid plexus, in the parenchymal and perivascular areas in the CNS and in close contact with peripheral nerves (Stead et al. 1987) . Mast cell tryptase, although being less potent than trypsin, can regulate neuronal activity by cleaving PAR2 (Steinhoff et al. 2000 , Reed et al. 2003 ) and other receptors. Selective PAR2 antagonist (FSLLRY-NH 2 ) was able to block paclitaxel induced neuropathic pain that was accompanied by mast cell tryptase activity in spinal cord and DRG in mice (Chen et al. 2011) . Tryptase is thus a strong candidate for neuronal PAR2 activation. There is a number of other possible PAR2 activators, such as P22, another trypsin-like serine protease with PAR2-activating capacity that has been detected in rat brain (Sawada et al. 2000) . Precursors of trypsin (trypsinogen-IV, trypsinogen-III) and other PAR2 activators (factor X) are also expressed in brain and human neural cell lines (Wiegand et al. 1993, Shikamoto and Morita 1999) .
The function of PAR2 in the nervous system
All four PARs are expressed throughout the peripheral and central nervous system and were suggested to play many different roles in neurogenic inflammation, pain perception, pruritus sensation, nerve regeneration, secretory functions and Ca 2+ mobilization (Corvera et al. 1999 , de Garavilla et al. 2001 , Linden et al. 2001 , Noorbakhsh et al. 2003 . Altogether, this published evidence suggests that PAR2 play an important role in the process of nociceptive transmission and in neurogenic inflammatory mechanisms both in the periphery and at the spinal cord level. The precise role and exact importance for spinal nociceptive modulation is not completely understood and needs further research. PAR2 co-expression in rat DRG neurons with TRPV4 receptors and neuropeptides SP and CGRP was also demonstrated (Grant et al. 2007 , Poole et al. 2013 . Activation of PAR2 sensitized TRPV4 receptors to agonist application due to PLC-β, PIP2, IP3, PLA, PKA, PKC and AA activation (Grant et al. 2007 , Poole et al. 2013 . These authors also showed that TRPV4 activation promoted SP and CGRP release from afferent nerves in the spinal cord and this process was enhanced by PAR2 agonist pretreatment. In vivo, intraplantar injection of PAR2 agonist resulted in mechanical hyperalgesia that was prevented in TRPV4 knock-out mice. The same PAR2 agonist treatment robustly enhanced hyperalgesia induced by the injection of TRPV4 agonist (Grant et al. 2007 ).
PAR2-induced activation of downstream protein kinases and other enzymes in neural tissue
PAR2 is co-expressed with TRPA1 in small DRG neurons (Dai et al. 2007 ). TRPA1 receptors could be activated by chemical compounds occurring in mustard, wasabi, garlic, onion or cinnamon, they are potential sensors for noxious cold and the mechanosensitivity is also suggested Schaefer 2007, Laursen et al. 2014) . Electrophysiological studies have shown that PAR2 sensitizes TRPA1, and this effect can be blocked by a PLC inhibitor (Dai et al. 2007) . Similarly it was shown that PAR2 activation of PKA and PLC also participate in TRPA1 mediated sensitization in nociceptive transmission (Wang et al. 2008 ).
In vivo it has been demonstrated that PAR2 mediates paclitaxel-induced mechanical, heat and cold hypersensitivity through the activation of TRPA1 (Chen et al. 2011 ).
Role of PAR2 in inflammatory, neuropathic and cancer pain
Critical involvement of PAR2 in the pathogenesis of several types of inflammatory or neuropathic pain was demonstrated previously (Bao et al. 2014) . PAR2 signaling is involved in the sensitization of peripheral nociceptors and dorsal horn neurons in several pathological pain states (Dai et al. 2007 , Grant et al. 2007 , Chen et al. 2011 . All this available information about the role of PAR2 in nociception and pain suggests that PAR2 may be an attractive target for the development of new options for pain treatment.
